AU2021269130A1 - SIRPα and SIRPβ1 antibodies and uses thereof - Google Patents

SIRPα and SIRPβ1 antibodies and uses thereof Download PDF

Info

Publication number
AU2021269130A1
AU2021269130A1 AU2021269130A AU2021269130A AU2021269130A1 AU 2021269130 A1 AU2021269130 A1 AU 2021269130A1 AU 2021269130 A AU2021269130 A AU 2021269130A AU 2021269130 A AU2021269130 A AU 2021269130A AU 2021269130 A1 AU2021269130 A1 AU 2021269130A1
Authority
AU
Australia
Prior art keywords
seq
antibody
acid sequence
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021269130A
Other languages
English (en)
Inventor
Sandip PANICKER
Eileen Lingshu ROSE
Adam David ROSENTHAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electra Therapeutics Inc
Original Assignee
Electra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc filed Critical Electra Therapeutics Inc
Publication of AU2021269130A1 publication Critical patent/AU2021269130A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AU2021269130A 2020-05-08 2021-05-10 SIRPα and SIRPβ1 antibodies and uses thereof Pending AU2021269130A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031541 WO2021226576A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021269130A1 true AU2021269130A1 (en) 2022-11-24

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021269130A Pending AU2021269130A1 (en) 2020-05-08 2021-05-10 SIRPα and SIRPβ1 antibodies and uses thereof
AU2021267943A Pending AU2021267943A1 (en) 2020-05-08 2021-05-10 SIRPα, SIRPβ1, and SIRPy antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021267943A Pending AU2021267943A1 (en) 2020-05-08 2021-05-10 SIRPα, SIRPβ1, and SIRPy antibodies and uses thereof

Country Status (11)

Country Link
US (4) US12503508B2 (cg-RX-API-DMAC7.html)
EP (2) EP4146699A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525298A (cg-RX-API-DMAC7.html)
KR (2) KR20230017793A (cg-RX-API-DMAC7.html)
CN (2) CN115768795A (cg-RX-API-DMAC7.html)
AU (2) AU2021269130A1 (cg-RX-API-DMAC7.html)
CA (2) CA3178038A1 (cg-RX-API-DMAC7.html)
GB (2) GB2613259A (cg-RX-API-DMAC7.html)
IL (2) IL297982A (cg-RX-API-DMAC7.html)
TW (2) TW202208430A (cg-RX-API-DMAC7.html)
WO (2) WO2021226591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
TW202330911A (zh) * 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性t細胞及其製作方法
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202547858A (zh) 2024-04-22 2025-12-16 美商電子療法股份有限公司 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) * 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
CN111511766B (zh) * 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
CR20200566A (es) * 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
MX2021015937A (es) 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.
EP4110819A1 (en) 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
EP4429768A2 (en) 2021-11-10 2024-09-18 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體

Also Published As

Publication number Publication date
US20230174648A1 (en) 2023-06-08
GB2613259A (en) 2023-05-31
JP2023525753A (ja) 2023-06-19
US20250197492A1 (en) 2025-06-19
US20230303685A1 (en) 2023-09-28
GB2613464A (en) 2023-06-07
KR20230017219A (ko) 2023-02-03
US12503508B2 (en) 2025-12-23
JP2023525298A (ja) 2023-06-15
EP4146698A1 (en) 2023-03-15
US12187797B2 (en) 2025-01-07
CN115768796A (zh) 2023-03-07
GB202218419D0 (en) 2023-01-18
AU2021267943A1 (en) 2022-11-24
CA3178038A1 (en) 2021-11-11
CN115768795A (zh) 2023-03-07
IL297982A (en) 2023-01-01
WO2021226591A1 (en) 2021-11-11
JP7894204B2 (ja) 2026-07-23
IL298024A (en) 2023-01-01
KR20230017793A (ko) 2023-02-06
CA3177961A1 (en) 2021-11-11
US20240239888A1 (en) 2024-07-18
GB202218421D0 (en) 2023-01-18
EP4146699A1 (en) 2023-03-15
TW202208431A (zh) 2022-03-01
WO2021226576A1 (en) 2021-11-11
TW202208430A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
US20230174648A1 (en) Sirp alpha and sirp beta 1 antibodies and uses thereof
US12600779B2 (en) LAG-3-binding molecules and methods of use thereof
US11845795B2 (en) NKp46 binding proteins
US11202828B2 (en) Therapeutic SIRP-α antibodies
EP3380196B1 (en) Heterodimeric antibodies that bind cd3 and cd38
JP2023511482A (ja) Cd276抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
US20240336686A1 (en) Novel multi-specific molecules
EP4429768A2 (en) Sirp gamma antibodies and uses thereof
WO2025085857A1 (en) Sirp antibodies for treatment of cancer
US20240360214A1 (en) LILRB1 and LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
WO2025226693A1 (en) Sirp gamma antibodies for treatment of epstein–barr virus infections